Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab ... - PR Newswire

Retrieved on: 2022-12-11 16:58:58

Tags for this article:

Drugs

Medicine

Monoclonal antibodies

janssen pharmaceutical

Click the tags to see associated articles and topics

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab ... - PR Newswire. View article details on HISWAI: https://www.prnewswire.com/news-releases/janssen-presents-first-data-from-majestec-2-trial-of-tecvayli-teclistamab-cqyv-in-combination-with-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-and-lenalidomide-in-relapsed-or-refractory-multiple-myeloma-301699764.html

Excerpt

... an immunomodulatory agent and an anti-CD38 monoclonal antibody.5 In August 2022, TECVAYLI™ received approval from the European Commission as ...

Article found on: www.prnewswire.com

View Original Article